Decreased brain dopaminergic transporters in HIV-associated dementia patients

Brain

Volumn 127, Issue 11, 2004, Pages 2452-2458

  Wang, Gene Jack ^a   Chang, Linda ^a,c   Volkow, Nora D ^b   Telang, Frank ^b   Logan, Jean ^a   Ernst, Thomas ^a   Fowler, Joanna S ^a  

^a BROOKHAVEN NATIONAL LABORATORY   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^c UNIVERSITY OF HAWAII   (United States)

Author keywords

Cocaine; Dementia; Dopamine; HIV; PET

Indexed keywords

CARBON 11; COCAINE; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; RACLOPRIDE;

ADULT; ARTICLE; BASAL GANGLION; BLOOD LEVEL; BRAIN REGION; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; CORPUS STRIATUM; DEMENTIA; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; FEMALE; HIV ASSOCIATED DEMENTIA; HIV COGNITIVE MOTOR COMPLEX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MOTOR DYSFUNCTION; NERVE ENDING; NERVE INJURY; NEUROTOXICITY; PARKINSON DISEASE; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; SUBCORTICAL DEMENTIA; VIRUS LOAD;

EID: 8144225856     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/awh269     Document Type: Article

References (30)

1. American Academy of Neurology AIDS Task Force Working Group. Report of a Working Group of the American Academy of Neurology AIDS Task Force. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type-1 (HIV-1) infection. Neurology 1991; 41: 778-85.
2. Aronow HA, Brew BJ, Price RW. The management of the neurological complications of HIV infection and AIDS. AIDS 1988; 2 Suppl 1: S151-9.
3. Aylward EH, Henderer JD, McArthur JC, Brettschneider PD, Harris GJ, Barta PE, et al. Reduced basal ganglia volume in HIV-1-associated dementia: results from quantitative neuroimaging. Neurology 1993; 43: 2099-104.
4. Berger J, Nath A. HIV dementia and the basal ganglia. Intervirology 1997; 40: 122-31.
5. Berger JR, Kumar M, Kumar A, Fernandez J, Levin B. Cerebrospinal fluid dopamine in HIV-1 infection. AIDS 1994; 8: 67-71.
6. Berger J, Nath A, Greenberg R, Andersen A, Greene R, Bognar A, et al. Cerebrovascular changes in the basal ganglia with HIV dementia. Neurology 2000; 54: 921-6.
7. Czub S, Koutsilieri E, Sopper S, Czub M, Stahl-Hennig C, Muller J, et al. Enhancement of central nervous system pathology in early simian immunodeficiency virus infection by dopaminergic drugs. Acta Neuropathol (Berl) 2001; 101: 85-91.
8. Gray F, Adle-Biassette H, Brion F, Ereau T, le Maner I, Levy V, et al. Neuronal apoptosis in human immunodeficiency virus infection. J Neurovirol 2000; 6 Suppl 1: S38-43.
9. Hinkin C, Castellon S, Hardy D, Farinpour R, Newton T, Singer E. Methylphenidate improves HIV-1-associated cognitive slowing. J Neuropsychiatry Clin Neurosci 2001; 13: 248-54.
10. Hriso E, Kuhn T, Masdeu J, Grundman M. Extrapyramidal symptoms due to dopamine-blocking agents in patients with AIDS encephalopathy. Am J Psychiatry 1991; 148: 1558-61.
11. Kaul M, Garden G, Lipton S. Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature 2001; 410: 988-94.
12. Khan Z, Koulen P, Rubinstein M, Grandy D, Goldman-Rakic P. An astroglia-linked dopamine D2-receptor action in prefrontal cortex. Proc Natl Acad Sci USA 2001; 98: 1964-9.
13. Kure K, Weidenheim KM, Lyman WD, Dickson DW. Morphology and distribution of HIV-1 gp41-positive microglia in subacute AIDS encephalitis. Acta Neuropathol (Berl) 1990; 80: 393-400.
14. Larsson M, Hagberg L, Forsman A, Norkrans G. Cerebrospinal fluid catecholamine metabolites in HIV-infected patients. J Neurosci Res 1991; 28: 406-9.
15. Logan J, Fowler J, Volkow N, Wang G, Ding Y-S, Alexoff D. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996; 16: 834-40.
16. Marie R, Barre L, Dupuy B, Viader F, Defer G, Baron J. Relationships between striatal dopamine denervation and frontal executive tests in Parkinson's disease. Neurosci Lett 1999; 260: 77-80.
17. Masliah E, Achim CL, Ge N, DeTeresa R, Terry RD, Wiley CA. Spectrum of human immunodeficiency virus-associated neocortical damages. Ann Neurol 1992; 32: 321-9.
18. Miller EN, Selnes OA, McArthur JC, Satz P, Becker JT, Cohen BA, et al. Neuropsychological performance in HIV-1 infected homosexual men: the Multicenter AIDS Cohort Study (MACS). Neurology 1990; 40: 197-203.
19. Miller G, Staley J, Heilman C, Perez J, Mash D, Rye D, et al. Immunochemical analysis of dopamine transporter protein in Parkinson's disease. Ann Neurol 1997; 41: 530-9.
20. Moszczynska A, Fitzmaurice P, Ang L, Kalasinsky K, Schmunk G, Peretti F, et al. Why is parkinsonism not a feature of human methamphetamine users? Brain 2004; 127: 363-70.
21. Nath A, Anderson C, Jones M, Maragos W, Booze R, Mactutus C, et al. Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia. J Psychopharmacol 2000; 14: 222-7.
22. Reyes M, Faraldi F, Senseng C, Flowers C, Fariello R. Nigral degeneration in acquired immune deficiency syndrome (AIDS). Acta Neuropathol (Berl) 1991; 82: 39-44.
23. Rottenberg DA, Sidtis JJ, Strother SC, Schaper KA, Anderson JR, Nelson MJ, et al. Abnormal cerebral glucose metabolism in HIV-1 seropositive subjects with and without dementia. J Nucl Med 1996; 37: 1133-41.
24. Sardar A, Czudek C, Reynolds G. Dopamine deficits in the brain: the neurochemical basis of parkinsonian symptoms in AIDS. Neuroreport 1996; 7: 910-12.
25. Scheel-Kruger J. Dopamine-GABA interactions: evidence that GABA transmits, modulates and mediates dopaminergic functions in the basal ganglia and the limbic system. Acta Neurol Scand Suppl 1986; 107: 1-54.
26. Scheller C, Sopper S, Jassoy C, ter Meulen V, Riederer P, Koutsilieri E. Dopamine activates HIV in chronically infected T lymphoblasts. J Neural Transm 2000; 107: 1483-9.
27. Volkow N, Fowler J, Gatley S, Logan J, Wang G, Ding Y, et al. PET evaluation of the dopamine system of the human brain. J Nucl Med 1996; 37: 1242-56.
28. Volkow N, Wang G, Fowler J, Fischman M, Foltin R, Abumrad N, et al. Methylphenidate and cocaine have a similar in vivo potency to block dopamine transporters in the human brain. Life Sci 1999; 65: PL7-12.
29. Volkow N, Chang L, Wang G, Fowler J, Leonido-Yee M, Franceschi D, et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 2001; 158: 377-82.
30. Wang G-J, Volkow N, Fowler J, Logan J, Pappas N, Wong C, et al. Reproducibility of repeated measures of endogenous dopamine competition with [C-11]raclopride in the human brain in response to methylphenidate. J Nuclear Med 1999; 40: 1285-91.